https://www.selleckchem.com/products/ZLN005.html
Programmed death-1 ligand (PD-L1) contributes to tumor immunosuppression and is upregulated in aggressive meningiomas. We performed a phase II study of nivolumab, a programmed death-1 (PD-1) blocking antibody among patients with grade ≥2 meningioma that recurred after surgery and radiation therapy. Twenty-five patients received nivolumab (240mg biweekly) until progression, voluntary withdrawal, unacceptable toxicity, or death. Tumor mutational burden (TM and quantification of tumor infiltrating lymphocytes (TIL) were evaluated as poten
Like
Comment
Share
